Antimicrobial Susceptibility Testing Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[236+ Pages Report] According to Facts & Factors, the global Antimicrobial Susceptibility Testing market size was estimated at USD 4.0 billion in 2025 and is expected to reach USD 7.0 billion by the end of 2034. The Antimicrobial Susceptibility Testing industry is anticipated to grow by a CAGR of 6.0% between 2026 and 2034. The Antimicrobial Susceptibility Testing Market is driven by rising antimicrobial resistance and increasing prevalence of infectious diseases globally.

Market Overview

The Antimicrobial Susceptibility Testing market encompasses diagnostic methods and tools used to determine the effectiveness of antimicrobial agents against specific microorganisms isolated from patient samples. This involves techniques such as disk diffusion, broth microdilution, automated systems, and molecular methods that guide appropriate antibiotic therapy by identifying resistance patterns. The market includes manual kits, automated instruments, culture media, and software for data interpretation, serving to optimize treatment outcomes, combat antimicrobial resistance, and support infection control in clinical settings without relying on empirical prescribing.

Key Insights

• As per the analysis shared by our research analyst, the Antimicrobial Susceptibility Testing market is estimated to grow annually at a CAGR of around 6.0% over the forecast period (2026-2034).
• In terms of revenue, the Antimicrobial Susceptibility Testing market size was valued at around USD 4.0 billion in 2025 and is projected to reach USD 7.0 billion by 2034.
• The Antimicrobial Susceptibility Testing Market is driven by escalating antimicrobial resistance and demand for rapid diagnostics.
• Based on the Type, the Automated Laboratory Instruments segment dominated the market in 2025 with a share of 45% due to faster results, higher throughput, and reduced manual errors in busy labs.
• Based on the Application, the Clinical Diagnostics segment dominated the market in 2025 with a share of 68%, owing to its essential role in guiding targeted antibiotic therapy for patient care.
• Based on the End-User, the Hospitals and Diagnostic Centers segment dominated the market in 2025 with a share of 55% because of the high volume of infectious disease testing and the need for quick turnaround times.
• North America dominated the global Antimicrobial Susceptibility Testing market in 2025 with a share of 38% attributed to advanced healthcare infrastructure, high R&D investments, and stringent regulatory focus on AMR.

Growth Drivers

• Rising Antimicrobial Resistance

The global surge in drug-resistant infections necessitates precise testing to select effective treatments, driving demand for advanced AST systems that provide rapid susceptibility profiles.

Technological innovations in automated and molecular methods reduce testing time from days to hours, improving patient outcomes and encouraging widespread adoption in clinical laboratories.

Restraints

• High Equipment Costs

Expensive automated instruments and reagents pose barriers for small labs in developing regions, limiting market penetration and slowing overall growth.

Regulatory complexities for approval of new AST methods delay product launches and increase development expenses for manufacturers.

Opportunities

• Point-of-Care Testing Expansion

Development of rapid, portable AST devices enables decentralized testing in remote areas, opening new markets in emerging economies with limited lab access.

Integration with AI for predictive resistance patterns offers advanced analytics, attracting investments in smart diagnostic solutions.

Challenges

• Standardization Issues

Variability in testing methods across labs can lead to inconsistent results, undermining clinical confidence and requiring ongoing harmonization efforts.

Shortage of skilled microbiologists hampers effective implementation of complex AST systems in resource-limited settings.

Report Scope

Market Segmentation

The Antimicrobial Susceptibility Testing market is segmented by type, application, end-user, and region.

Based on Type Segment, the Antimicrobial Susceptibility Testing market is divided into manual antimicrobial susceptibility testing products, automated laboratory instruments, culture and growth media, consumables, and others. The most dominant segment is Automated Laboratory Instruments, followed by Manual Antimicrobial Susceptibility Testing Products. Automated Laboratory Instruments dominate because they offer high-throughput processing, reduced human error, and integration with lab information systems, which accelerates diagnostic workflows in high-volume hospitals and drives market expansion through efficiency gains and cost savings over time.

Based on Application Segment, the Antimicrobial Susceptibility Testing market is divided into clinical diagnostics, drug discovery and development, epidemiology, and others. The most dominant segment is Clinical Diagnostics, followed by Drug Discovery and Development. Clinical Diagnostics leads the segment due to its critical role in patient-specific antibiotic selection amid rising infections, ensuring targeted therapy that minimizes resistance development and propels market growth via widespread lab adoption and regulatory support for accurate testing.

Based on End-User Segment, the Antimicrobial Susceptibility Testing market is divided into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research and academic institutes, and others. The most dominant segment is Hospitals and Diagnostic Centers, followed by Pharmaceutical and Biotechnology Companies. Hospitals and Diagnostic Centers dominate because they handle the majority of infectious disease cases requiring immediate AST results for treatment decisions, fostering high-volume procurement that stimulates technological advancements and sustains market momentum through essential healthcare integration.

Recent Developments

• In March 2025, bioMérieux launched VITEK REVEAL, a rapid AST system providing results in 2-6 hours for bloodstream infections, enhancing sepsis management.
• In June 2025, Thermo Fisher Scientific acquired Accelerate Diagnostics, expanding its AST portfolio with innovative phenotypic testing technologies.
• In September 2025, Becton Dickinson introduced an AI-powered module for its BD Phoenix system to predict antimicrobial resistance patterns.
• In November 2025, Danaher Corporation partnered with the CDC for AMR surveillance using advanced molecular AST platforms.
• In January 2026, Bio-Rad Laboratories released new QC strains for AST validation, supporting lab accreditation requirements.

Regional Analysis

• North America to dominate the global market

North America leads the Antimicrobial Susceptibility Testing market through robust healthcare systems, high R&D investments, and stringent regulatory frameworks addressing AMR. Advanced lab infrastructure and government initiatives like the CDC's AR Lab Network drive innovation and adoption. The United States dominates within North America with its extensive diagnostic networks, leadership in biotech, and federal funding for combating superbugs through rapid testing technologies.

Europe holds a strong position in the Antimicrobial Susceptibility Testing market, supported by EU-wide AMR strategies, collaborative research programs, and harmonized standards for diagnostics. Focus on stewardship programs accelerates AST integration. Germany dominates within Europe through its precision engineering in lab instruments, strong pharma sector, and central role in EU surveillance networks for resistance monitoring.

Asia Pacific is witnessing rapid growth in the Antimicrobial Susceptibility Testing market, fueled by rising infections, expanding hospitals, and government efforts to curb AMR. China dominates within Asia Pacific with massive healthcare reforms, large patient volumes, and investments in domestic AST manufacturing to meet local demand.

Latin America shows steady expansion in the Antimicrobial Susceptibility Testing market, driven by improving diagnostics and AMR awareness. Brazil dominates the region with its growing public health initiatives and adoption of automated systems in urban hospitals.

The Middle East & Africa region exhibits emerging potential in the Antimicrobial Susceptibility Testing market, supported by healthcare modernization. South Africa leads within the region through its advanced labs and focus on combating resistant infections in high-burden areas.

Competitive Analysis

The global Antimicrobial Susceptibility Testing market is dominated by players:

• bioMérieux SA
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Bio-Rad Laboratories Inc.
• Accelerate Diagnostics, Inc.
• Merck KGaA
• Bruker Corporation
• Roche Diagnostics
• Liofilchem S.r.l.

The global Antimicrobial Susceptibility Testing market is segmented as follows:

By Type

• Manual Antimicrobial Susceptibility Testing Products
• Automated Laboratory Instruments
• Culture and Growth Media
• Consumables

By Application

• Clinical Diagnostics
• Drug Discovery and Development
• Epidemiology
• Others

By End-User

• Hospitals and Diagnostic Centers
• Pharmaceutical and Biotechnology Companies
• Research and Academic Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America